Back to Top
  • Psychedelic Medicine will publish Volume 1, Issue 1 in March 2023 and is open for submissions now! Visit our Information for Authors for details on how to submit your reasearch today!

Aims & Scope

Coming in 2023!

Psychedelic substances, which primarily act as serotonin 2A receptor agonists, are rapidly moving into the mainstream as clinical research programs and legalization/decriminalization measures accelerate in North America, United Kingdom, and Europe. Psychedelic substances undergoing research in preclinical and clinical studies include psilocybin, ayahuasca, DMT, 5-MeO-DMT, LSD, and mescaline/peyote. Patients and clinicians are increasingly optimistic about the potential efficacy of psychedelic drugs as an alternative or supplement to traditionally manufactured pharmaceuticals to treat depression, anxiety, addiction, demoralization, and other mental health conditions. Preliminary clinical studies indicate that, when administered responsibly, psychedelic agents may be safe and effective therapeutics with intriguing effects on the CNS, brain function, and inflammation.

Launching in 2023, Psychedelic Medicine will provide rapid, fair peer-review, and welcomes original research papers on every aspect of psychedelic medicine including basic science, clinical, and translational research, as well as medical applications.

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.